You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Angstrom Bio is developing a rapid, scalable coronavirus test that uses nanopore sequencing to detect barcoded PCR products.
The firm is also pursuing advances in its manufacturing and ordering processes that it says will help it scale to $500 million in annual revenues.
Developed by researchers at Yale University, the method, called deterministic barcoding in tissue sequencing, can map thousands of genes at 10 micron resolution.
Adaptive is rebranding its immunoSeq Dx assay as T-Detect and plans to submit for an EUA for a COVID-19 T-Cell response test by the end of the year.
In their first conference call with investors, PacBio's new CEO and CFO laid out a strategic plan for the company as it weathers the COVID-19 pandemic.
At the ASHG 2020 virtual meeting, researchers presented data showing they could use the method to enrich for placental DNA in maternal plasma samples.
Antibacterial and psychiatric drugs could counteract gene expression patterns seen in COVID-19, according to data presented at the virtual ASHG conference.
The firm's CLIA lab presented data at the virtual ASHG meeting showing how it validated WGS-based STR expansion analysis to diagnose rare disease.
Researchers from the Broad Institute and MIT have used RNA editing and single-cell RNA sequencing to record when RNA molecules were transcribed.
The new plate-based protocol developed at the Karolinska Institute combines low-coverage WGS and SMART-Seq2 transcriptomics for single-cells.
Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.
Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.
The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.
In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.